Lloyd Doggett
Suspicious Timing Detected
4 flagsRep. Doggett bought $1,001 - $15,000 in $PG on 2026-02-17, 6 days after HR7502 was introduced, which proposes a federal standard for 'recycled content' claims that could increase compliance costs for companies like Procter & Gamble.
Rep. Doggett bought $1,001 - $15,000 in $PG on 2026-02-17, 33 days after S3677, the "Dietary Supplement Listing Act of 2026," was introduced, which mandates pre-market listing for dietary supplements, potentially increasing regulatory burdens for companies in this sector.
Rep. Doggett bought $1,001 - $15,000 in $PG on 2026-02-17, 34 days after HR7050, the "Homeopathic Drug Product Safety, Quality, and Transparency Act," was introduced, which would introduce stringent FDA oversight for homeopathic products, impacting related industries.
Rep. Doggett bought $1,001 - $15,000 in $PG on 2026-02-17, 62 days after HR6832 was introduced, which aims to amend the Federal Trade Commission Act to include requirements for recyclable, compostable, and reusable claims for consumer product packaging, potentially increasing compliance costs for consumer goods manufacturers.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Homeopathic Drug Product Safety, Quality, and Transparency Act
The Homeopathic Drug Product Safety, Quality, and Transparency Act introduces stringent FDA oversight for homeopathic products, effectively reclassifying them as drugs requiring pre-market approval. This eliminates the current regulatory loophole benefiting manufacturers, leading to significant compliance costs and market contraction for companies currently selling these products.
To prohibit a person from making a misleading recycled content claim in advertising, marketing, selling, or offering for sale a product to a consumer, and for other purposes.
HR7502, currently in the early stages of the legislative process, proposes a federal standard for 'recycled content' claims, which would increase compliance and operational costs for consumer goods and packaging manufacturers. Companies making unsubstantiated claims face Federal Trade Commission enforcement actions, leading to increased legal and operational expenses. This bill directly impacts profitability for companies relying on recycled content claims in their marketing.
To amend the Federal Trade Commission Act to include requirements for recyclable, compostable, and reusable claims for packaging for a consumer product, and for other purposes.
The PACK Act (HR6832) introduces new compliance costs for consumer packaged goods manufacturers by imposing strict requirements on recyclability and compostability claims. This bill, currently in the early stages of the legislative process, creates a regulatory burden for companies like Procter & Gamble, Coca-Cola, PepsiCo, Kraft Heinz, Clorox, General Mills, and Mondelez International. The market data shows mixed performance for these companies over the past 7 and 30 days, with some experiencing declines.
Dietary Supplement Listing Act of 2026
The Dietary Supplement Listing Act of 2026, S.3677, mandates pre-market listing for dietary supplements, increasing regulatory burden and compliance costs. This legislation is in its early stages, having been introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions on January 15, 2026. The bill is expected to consolidate the market, benefiting larger, established consumer goods and healthcare companies while pressuring smaller, independent supplement manufacturers.
Baby Bonus Act
The 'Baby Bonus Act' establishes direct payments to parents starting January 1, 2026, increasing disposable income for families with children. This directly benefits consumer goods companies focused on infant and child products and pediatric healthcare providers. The bill creates a new federal program, ensuring a sustained revenue stream for affected industries.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 authorizes the President to grant normal trade relations (NTR) status to most countries, excluding Belarus, Cuba, and North Korea, by waiving the Jackson-Vanik amendment. This action reduces tariffs and trade barriers for goods from these countries, directly benefiting U.S. importers and consumers through lower costs. Companies relying on global supply chains will see improved margins and increased access to goods.
Baby Changing in Health Centers Act
HR6370 mandates baby changing tables in health centers receiving federal grants, creating a new procurement requirement. This bill directly impacts manufacturers of commercial baby changing stations and sanitary products. The financial impact is limited to specific health centers and does not represent a broad market shift.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.